-
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 June 2019
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 June 2019
-
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 June 2019
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 June 2019
The PRAC starts a new review of leuprorelin medicines after reports of handling errors during preparation and administration.
-
Strengthening engagement between EMA and general practitioners / family physicians
Strengthening engagement between EMA and general practitioners / family physicians
-
Strengthening engagement between EMA and general practitioners / family physicians
Strengthening engagement between EMA and general practitioners / family physicians
EMA, the European Union of General Practitioners (UEMO), the European section of the World Organization of Family doctors (WONCA) and the European Forum for Primary Care (EFPC) sign a joint statement committing to strengthened collaboration.
-
Quality requirements for medical devices in combination products: guideline open for public consultation
Quality requirements for medical devices in combination products: guideline open for public consultation
-
Quality requirements for medical devices in combination products: guideline open for public consultation
Quality requirements for medical devices in combination products: guideline open for public consultation
The guideline covers human medicines that include a medical device, known as drug-device combinations. Comments on the guideline can be submitted until 31 August 2019.
-
Engaging early with medicine developers to combat antimicrobial resistance
Engaging early with medicine developers to combat antimicrobial resistance
-
Engaging early with medicine developers to combat antimicrobial resistance
Engaging early with medicine developers to combat antimicrobial resistance
EMA is opening its forum for early dialogue on innovative medicines to the developers of new antimicrobials.
